Inhibition of hepatocellular carcinoma by fulvestrant involves the estrogen receptor α and Wnt pathways in vitro and in patients

Publisher： Spandidos Publications

E-ISSN： 1791-3004|10|6|3125-3131

ISSN： 1791-2997

Source： Molecular Medicine Reports, Vol.10, Iss.6, 2014-01, pp. : 3125-3131

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Targeting Receptor Tyrosine Kinase Pathways in Hepatocellular Carcinoma

By  

Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents), Vol. 11, Iss. 6, 2011-07 ,pp. : 560-575

Bentham Science Publishers

Access to resources Recommend Favorite

Fulvestrant (ICI 182,780) sensitizes breast cancer cells expressing estrogen receptor α to vinblastine and vinorelbine

By Sui Meihua  

Breast Cancer Research and Treatment, Vol. 121, Iss. 2, 2010-06 ,pp. : 335-345

Springer Publishing Company

Access to resources Recommend Favorite

HBx protein-induced upregulation of microRNA-221 promotes aberrant proliferation in HBVrelated hepatocellular carcinoma by targeting estrogen receptor-α

By  

Oncology Reports, Vol. 33, Iss. 2, 2015-01 ,pp. : 792-798

Spandidos Publications

Access to resources Recommend Favorite

A phase II neoadjuvant trial of anastrozole, fulvestrant, and gefitinib in patients with newly diagnosed estrogen receptor positive breast cancer

By Massarweh Suleiman  

Breast Cancer Research and Treatment, Vol. 129, Iss. 3, 2011-10 ,pp. : 819-827

Springer Publishing Company

Access to resources Recommend Favorite

Expression of estrogen receptor α and β in esophageal squamous cell carcinoma

By                    

Oncology Reports, Vol. 30, Iss. 6, 2013-01 ,pp. : 2771-2776

Spandidos Publications

Access to resources Recommend Favorite